You're missing the big trend.
You're missing the big trend. In addition to the availability of DIY hardware and more ways for patients to find each other and communicate, other developed or developing countries are approving treatments before the FDA. The size of the US market still holds back medical research, but at some point in this century, the size of the "early adopter" markets with sufficient buying power will be big enough that it won't matter. Signed, one American Type 1 diabetic who is tired of the FDA letting us die by keeping the best tools out of our hands. P.S. If an analogy helps you, think about how music piracy ended up giving us Spotify, and how it had to come from Europe to break into the US market, and how it blocked Americans to avoid getting shut down in its early days. Or, think about how Jobs essentially tricked the labels into allowing iTunes. The traditional record label publishing model is analogous to the FDA's drug trial model. The FDA can make any number of arguments about how their method is more rigorous and beneficial, but at some point, newer methods of getting similar results are coming along, and at some point after that, those methods will be backed by a power with the resources and inclination to bring the benefits of rigor to the new methods without resorting to the old methods.
Posted by 1123581321 on Feb 13, 2015, 3:51 AM
Tags
Related issues
- [Bug]: Downloads fail with "Got more than 8190 bytes when reading" due to GitHub's new 9KB+ CSP header on release redirects
- Investigate path resolution for "libflutter.so" binary
- Although I'm very hesitant to put too much faith into anything in the area of nutrition and health based on a single study, I do recall r...
- I don't know the demographics of your students but I'm always intrigued when I'm able to quickly get productive with what I'm currently l...
- > hopefully slow down the trend of the elites making massive amounts of money with financial transactions instead of BUILDING THINGS and ...
- If you want to be utilitarian about it, maximizing common good derived from a modest donation, then pick (a) the venture that will produc...
Raise real-world problems, find people facing the same issue, and discuss solutions.8,000 issues0 comments
reliability (Healthcare)
[Bug]: Downloads fail with "Got more than 8190 bytes when reading" due to GitHub's new 9KB+ CSP header on release redirects
Investigate path resolution for "libflutter.so" binary
Although I'm very hesitant to put too much faith into anything in the area of nutrition and health based on a single study, I do recall r...
I don't know the demographics of your students but I'm always intrigued when I'm able to quickly get productive with what I'm currently l...
> hopefully slow down the trend of the elites making massive amounts of money with financial transactions instead of BUILDING THINGS and ...
If you want to be utilitarian about it, maximizing common good derived from a modest donation, then pick (a) the venture that will produc...
I really think we're dealing with some very complicated biochemistry here.
The human angle behind these stories transcends way beyond the business one.
You're missing the big trend.
You're missing the big trend. In addition to the availability of DIY hardware and more ways for patients to find each other and communicate, other developed or developing countries are approving treatments before the FDA. The size of the US market still holds back medical research, but at some point in this century, the size of the "early adopter" markets with sufficient buying power will be big enough that it won't matter. Signed, one American Type 1 diabetic who is tired of the FDA letting us die by keeping the best tools out of our hands. P.S. If an analogy helps you, think about how music piracy ended up giving us Spotify, and how it had to come from Europe to break into the US market, and how it blocked Americans to avoid getting shut down in its early days. Or, think about how Jobs essentially tricked the labels into allowing iTunes. The traditional record label publishing model is analogous to the FDA's drug trial model. The FDA can make any number of arguments about how their method is more rigorous and beneficial, but at some point, newer methods of getting similar results are coming along, and at some point after that, those methods will be backed by a power with the resources and inclination to bring the benefits of rigor to the new methods without resorting to the old methods.
Comments (0)
No comments yet. Start the discussion.